România - română - ANMDM (Agenția Națională a Medicamentului și a Dispozitivelor Medicale din România)

ratiopharm gmbh - caspofunginum - pulb. pt. conc. pt.sol. perf. - 50mg - antimicotice de uz sistemic alte antimicotice sistemice

România - română - ANMDM (Agenția Națională a Medicamentului și a Dispozitivelor Medicale din România)

ratiopharm gmbh - caspofunginum - pulb. pt. conc. pt.sol. perf. - 70mg - antimicotice de uz sistemic alte antimicotice sistemice

Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

merck sharp & dohme b.v. - caspofunginum - pulbere pentru concentrat pentru soluţie perfuzabilă - 50 mg

Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

merck sharp & dohme b.v. - caspofunginum - pulbere pentru concentrat pentru soluţie perfuzabilă - 70 mg

România - română - ANMDM (Agenția Națională a Medicamentului și a Dispozitivelor Medicale din România)

pharmadox healthcare ltd. - malta - caspofunginum - pulb. pt. conc. pt. sol. perf. - 50mg - antimicotice de uz sistemic alte antimicotice sistemice

România - română - ANMDM (Agenția Națională a Medicamentului și a Dispozitivelor Medicale din România)

pharmadox healthcare ltd. - malta - caspofunginum - pulb. pt. conc. pt. sol. perf. - 70mg - antimicotice de uz sistemic alte antimicotice sistemice

România - română - ANMDM (Agenția Națională a Medicamentului și a Dispozitivelor Medicale din România)

lek pharmaceuticals d.d. - slovenia - caspofunginum - pulb. pt. conc. pt. sol. perf. - 50mg - antimicotice de uz sistemic alte antimicotice sistemice

România - română - ANMDM (Agenția Națională a Medicamentului și a Dispozitivelor Medicale din România)

lek pharmaceuticals d.d. - slovenia - caspofunginum - pulb. pt. conc. pt. sol. perf. - 70mg - antimicotice de uz sistemic alte antimicotice sistemice

Uniunea Europeană - română - EMA (European Medicines Agency)

krka, d.d., novo mesto  - lenalidomide hydrochloride monohydrate - multiple myeloma; myelodysplastic syndromes; lymphoma, follicular; lymphoma, mantle-cell - imunosupresoare - multiple myelomalenalidomide krka as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) este indicat pentru tratamentul pacienților adulți cu mielom multiplu netratați anterior, care nu sunt eligibili pentru transplant. lenalidomide krka in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. mantle cell lymphomalenalidomide krka as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (see sections 4. 4 și 5. follicular lymphomalenalidomide krka in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a). multiple myelomalenalidomide krka as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) este indicat pentru tratamentul pacienților adulți cu mielom multiplu netratați anterior, care nu sunt eligibili pentru transplant. lenalidomide krka in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. mantle cell lymphomalenalidomide krka as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (see sections 4. 4 și 5. follicular lymphomalenalidomide krka in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).

Uniunea Europeană - română - EMA (European Medicines Agency)

merck sharp & dohme b.v. - caspofungin (as acetate) - candidiasis; aspergillosis - antimicotice pentru uz sistemic - treatment of invasive candidiasis in adult or paediatric patients;treatment of invasive aspergillosis in adult or paediatric patients who are refractory to or intolerant of amphotericin b, lipid formulations of amphotericin b and / or itraconazole. refractoriness is defined as progression of infection or failure to improve after a minimum of seven days of prior therapeutic doses of effective antifungal therapy;empirical therapy for presumed fungal infections (such as candida or aspergillus) in febrile, neutropaenic adult or paediatric patients.